Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 8/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.62 |
| ▸ | KDR | P35968 | 6/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 8/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4476484 | 0.99 | PDGFRA (0.64) | PDGFRAFGFR2KDRKITMET | |
| SCHEMBL4472096 | 0.96 | FGFR2 (0.68) | PDGFRAFGFR2KDRKITMET | |
| SCHEMBL13936798 | 0.95 | FGFR2 (0.65) | PDGFRAFGFR2KDRKITMET | |
| Hydrochloric Acid SCHEMBL4475152 | 0.95 | FGFR2 (0.67) | PDGFRAFGFR2KDRKITMET | |
| Hydrochloric Acid SCHEMBL4475260 | 0.95 | FGFR2 (0.64) | PDGFRAFGFR2KDRKITMET | |
| SCHEMBL4476674 | 0.94 | PDGFRA (0.60) | PDGFRAFGFR2KDRKITMET | |
| Hydrochloric Acid SCHEMBL4488357 | 0.93 | PDGFRA (0.60) | PDGFRAFGFR2KDRKITMET | |
| SCHEMBL4467280 | 0.93 | PDGFRA (0.62) | PDGFRAFGFR2KDRKITMET | |
| SCHEMBL4482846 | 0.93 | FGFR2 (0.68) | PDGFRAFGFR2KDRMET | |
| SCHEMBL4465009 | 0.93 | FGFR2 (0.68) | PDGFRAFGFR2KDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | claimed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | PDGFRA 229/4885FGFR2 1020/4885KDR 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.